Valeant Canada relocates U.S. production of Jublia® from Tokyo, Japan to Laval, Quebec
LAVAL, QC, Jan. 19, 2016 /CNW Telbec/ - Valeant Canada is pleased to announce that Valeant's Laval-based plant will become the North American production site for the prescription medication Jublia®, a topical solution that effectively treats toenail fungus. The United States (U.S.) production represents nearly 80% of the total volume of Jublia®, which was previously manufactured in Tokyo, Japan and packaged in the U.S.
So far, this relocation has generated a total investment of over $1 million for the Laval plant. This investment has helped fund the changes to the medication's packaging, the construction of highly specialized rooms used to manipulate ethanol, and new and improved flammable safety storage units. The Laval plant now meets global standards and can safely handle a significant increase in production volumes.
Generating new business through performance
"Laval is a strategic choice for Valeant. This facility's lean, state-of-the-art, high-tech manufacturing and efficient production processes have made us competitive on the global stage and helped set our performance apart," said Jacques Dessureault, President and General Manager of Valeant Canada. "As we take on the role of global production center for prescription dermatology products, this now world-class facility allows us to become a major player in our industry at home and abroad." Given this, we believe some European countries may consider sending their production to Laval once they launch Jublia®.
"With this news, it is evident that Valeant Canada is making concrete contributions to the continued development of the Laval life sciences ecosystem," said Jean-Marc Juteau, Director of Cité de la Biotech.
Securing High Quality Jobs
This transfer of production to Laval also guarantees the maintenance of many specialized manufacturing jobs in Quebec, which leads into the continued sustenance and growth of Valeant Canada's operations over the medium term. Moreover, outsourced contractors will also benefit from the expansion of production at the Laval site, including maintenance, construction and IT services, among others.
Jublia® (efinaconazole 10% topical solution), is the first topical triazole antifungal agent developed for distal lateral subungual onychomycosis (DLSO). Jublia® (efinaconazole 10%) offers physicians and their patients a treatment with a superior therapeutic value in the fight against nail fungus.
About Valeant Canada
Valeant Canada, a subsidiary of Valeant Pharmaceuticals International Inc., is a multinational specialty pharmaceutical company that develops, manufactures, and markets a broad range of pharmaceutical products, primarily in the areas of dermatology, eye health, cardio-metabolic, neurology, and branded generics. More information about Valeant Canada can be found at www.valeantcanada.com.
SOURCE Valeant Canada
For further information: Sébastien Beauchamp, Valeant Canada LP, Tél. : 514-744-6792, Courriel : firstname.lastname@example.org